Clinical Research Associate II
10/26/2025,
Summit Therapeutics
Menlo Park, CA
Clinical Research Associate | Research Associate
About Summit:
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational
bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a...